We are proudly supporting clinical trials across Australia to benefit people with cancer
Currently, we support the delivery of over ten clinical trials for cancer patients across Australia. These clinical trials:
- Conduct research on the safety and effectiveness of new medications and treatment
- Validate the use of treatments against the current standard of care
- Study the impact on early diagnosis, cancer prevention or quality of life
Many other trials are also under development and will be available for patients in the future. Our goal is to continue to contribute to the development of new cancer treatments and techniques that will make a lasting difference.
Clinical trials supported by Icon Cancer Foundation
OP-1250-001
A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer (OP-1250-001)
Locations
Wesley
Diagnosis
Breast cancer
Open for recruitment
View Trial
LEAD-4-BCS
A feasibility study evaluating a structured telehealth Lifestyle intervention (Exercise And Diet) for early-stage Breast Cancer Survivors (LEAD-4-BCS) undergoing neo-adjuvant/ adjuvant chemotherap
Locations
Revesby
Diagnosis
Breast cancer
Opening soon
View Trial
REFOCUS RLY-4008-101
A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
OP-1250-002
A Phase 1 Dose Escalation and Expansion Open-label, Multicenter, Study of OP-1250 in Combination With the CDK4/6 Inhibitor Palbociclib in Adult Subjects With Advanced or Metastatic HR-positive, HER2-negative Breast Cancer (OP-1250-002)
Locations
Wesley, Southport
Diagnosis
Breast cancer
Open for recruitment
View Trial
SHR-A1921-I-102
A Phase 1 Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1921 in Subjects With Advanced Malignant Solid Tumour .
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Opening soon
View Trial
BGB-24714-101
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and in Combination With Chemotherapy in Patients With Advanced or Metastatic Solid Tumors
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
RC198-G001
A Phase 1, First-In-Human, Multicenter, Open-Label Study in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
Locations
Wesley
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
ATRIUM ATG-018-001
A Phase 1, Open-Label, Multi-Center, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-018 (ATR inhibitor) Treatment in Patients with Advanced Solid Tumors and Hematological Malignancies
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
PXS5505-MF-101
A Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Postpolycythemia Vera or Post-essential Thrombocythemia Myelofibrosis
Locations
Adelaide (Kurralta Park)
Diagnosis
Myeloproliferative disorders
Open for recruitment
View Trial
DB-1303-O-1001
A Phase 1/2a, Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303 in Patients With Advanced/Metastatic Solid Tumors. (DB-1303-O-1001)
Locations
South Brisbane
Diagnosis
Breast cancer, Endometrial cancer
Open for recruitment
View Trial
ADG116-1003
A Phase 1b Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients
Locations
Adelaide (Kurralta Park)
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
CodeBreak-101 20190135
A Phase 1b/2, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
BA3011-002
A Phase 2 Study of BA3011 Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer Who Had Prior Disease Progression on a PD-1/L1, EGFR, or ALK Inhibitor
Locations
Central Building (Oncology)
Diagnosis
Lung cancer
Open for recruitment
View Trial
ASPEN-06 AT148006
A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma
Locations
Southport
Diagnosis
Gastric / gastroesophageal cancer
Opening soon
View Trial
ASPEN 06
A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)
Locations
Farrer Park
Diagnosis
Gastric / gastroesophageal cancer
Open for recruitment
View Trial
BRUIN MCL-321
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma
Locations
Wesley
Diagnosis
Lymphoma – Hodgkin’s
Open for recruitment
View Trial
Viktoria-1 CELC-G-301
A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy
Locations
Southport
Diagnosis
Breast cancer
Open for recruitment
View Trial
Viktoria-1
A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy
Locations
Farrer Park
Diagnosis
Breast cancer
Open for recruitment
View Trial
UP-NEXT MER-XMT-1536-3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent, Platinum-Sensitive Ovarian Cancer (UP-NEXT)
Locations
Chermside, Southport, Wesley
Diagnosis
Ovarian cancer
Open for recruitment
View Trial
AFFIRM-AL NEOD001-301
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis
Locations
South Brisbane, Wesley
Diagnosis
Amyloidosis
Open for recruitment
View Trial
HERTHENA–Lung02
A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-Based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-Mutated (EGFRm) Non-Small Cell Lung Cancer (NSCLC) After Failure of EGFR Tyrosine Kinase Inhibitor (TKI) Therapy.
Locations
Mount Alvernia
Diagnosis
Lung cancer
Open for recruitment
View Trial
CONTACT-02 XL184-315
A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Locations
Chermside, Wesley
Diagnosis
Prostate cancer
Open for recruitment
View Trial
VERITAC-2 C4891001
A Phase 3, Randomized, Open-Label, Multicenter Trial of ARV-471 (PF-07850327) VS Fulvestrant in Participants with Estrogen Receptor-Positive, HER-2-Negative Advanced Breast Cancer whose Disease Progressed after Prior Endocrine Based Treatment for Advanced Disease (VERITAC-2)
Locations
Hobart
Diagnosis
Breast cancer
Open for recruitment
View Trial
SHR-2002-102
A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SHR-2002 Injection in Combination With SHR-1316 in Patients With Advanced Malignant Tumors
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
LM108-01-101
A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
CAPTURE BCT1901
A phase II randomised study to evaluate alpelisib plus fulvestrant versus capecitabine in oestrogen receptor positive, HER2-negative advanced breast cancer patients with PIK3CA mutant circulating DNA.
Locations
Hobart
Diagnosis
Breast cancer
Open for recruitment
View Trial
STELLAR 303
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Locations
Farrer Park
Diagnosis
Colorectal cancer
Open for recruitment
View Trial
KRYSTAL-12
A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
Locations
Farrer Park
Diagnosis
Lung cancer
Open for recruitment
View Trial
HLX10-020-SCLC302
A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 or Placebo in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
Locations
Wesley
Diagnosis
Lung cancer
Open for recruitment
View Trial
BGB-A317-LBL-007-201
A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer
Locations
South Brisbane
Diagnosis
Colorectal cancer
Open for recruitment
View Trial
AK112-101
A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors
Locations
South Brisbane, Adelaide (Kurralta Park)
Diagnosis
Advanced solid tumours, Ovarian cancer
Open for recruitment
View Trial
RINGSIDE AL-DES-01
A Study of AL102 in Patients With Progressing Desmoid Tumors
Locations
Adelaide (Kurralta Park)
Diagnosis
Sarcoma
Open for recruitment
View Trial
ABSK043-101
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
BRIGHTLINE-1
A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
Locations
Adelaide (Kurralta Park)
Diagnosis
Sarcoma
Open for recruitment
View Trial
liDERA GO42784
A study to evaluate the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician’s Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer.
Locations
Hobart, Wesley, Adelaide (Kurralta Park)
Diagnosis
Breast cancer
Open for recruitment
View Trial
AK127-101
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours
Locations
Adelaide (Kurralta Park)
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
AML M22
AMLM22/D1: The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in patients with acute myeloid leukaemia in first complete remission.
Locations
South Brisbane, Wesley, Chermside, Southport
Diagnosis
Leukaemia
Open for recruitment
View Trial
REGENERON_ R1979-ONC-1625
An open-label study to assess the anti-tumor activity and safety of REGN1979, an Anti-CD20 X Anti-CD3 bispecific antibody, in patients with relapsed or refractory follicular lymphoma
Locations
Farrer Park
Diagnosis
Lymphoma – B-cell Non Hodgkin’s
Open for recruitment
View Trial
DESTINY-B12 D9673C00007
An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12)
Locations
Wesley
Diagnosis
Breast cancer
Open for recruitment
View Trial
ALLG NBCR
Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry
Locations
Wesley
Diagnosis
Leukaemia
Open for recruitment
View Trial
BGB-A317-15025-101
BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors
Locations
Adelaide (Kurralta Park)
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
LIBERATE
Clinical registry of focal low dose rate brachytherapy in men with biopsy confirmed low-intermediate risk prostate cancer (LIBERATE)
Locations
Epworth Richmond, Epworth Freemasons, Geelong
Diagnosis
Prostate cancer
Open for recruitment
View Trial
CONSOLE
Conventional or Stereotactic Radiotherapy for the palliation of non-spine bone metastases: A randomised phase III trial. (CONSOLE)
Locations
Wahroonga
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
DECREASE TROG 19.06
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA
Locations
Epworth Richmond
Diagnosis
Prostate cancer
Open for recruitment
View Trial
DASL-HiCaP ANZUP1801
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (DASL-HiCaP)
Locations
Gold Coast University Hospital, Wahroonga, Gold Coast Private, Southport, Adelaide (Kurralta Park), Hobart
Diagnosis
Prostate cancer
Open for recruitment
View Trial
DECRESCENDO BCT2002 BIG19-02
De-escalation Adjuvant Chemo in HER2+/ER-/Node-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo & Dual HER2 Blockade
Locations
Wesley, Hobart
Diagnosis
Breast cancer
Open for recruitment
View Trial
DREAM3R
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma (DREAM3R)
Locations
South Brisbane, Wesley, Chermside
Diagnosis
Mesothelioma
Open for recruitment
View Trial
PHI-101-001
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML
Locations
Wesley
Diagnosis
Leukaemia
Open for recruitment
View Trial
ASPEN-04
Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Locations
Adelaide (Kurralta Park)
Diagnosis
Head and neck cancer
Open for recruitment
View Trial
ASPEN-03
Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Locations
Adelaide (Kurralta Park)
Diagnosis
Head and neck cancer
Open for recruitment
View Trial
EXPERT BCT1601
EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer (EXPERT)
Locations
Epworth Richmond
Diagnosis
Breast cancer
Open for recruitment
View Trial
ERUPT
External beam Radiotherapy and Urethral strictures in Prostate cancer Treatment (ERUPT)
Locations
Toowoomba
Diagnosis
Prostate cancer
Open for recruitment
View Trial
MER-XMT-1536-1
First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
HyperArc Registry VAR-2019-01
HyperArc Registry Study
Locations
Canberra, Greenslopes, Gold Coast Private, Maroochydore
Diagnosis
Brain cancer
Open for recruitment
View Trial
I-MAT MASC 03.18
Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma
Locations
Hobart
Diagnosis
Skin cancer – non-melanoma
Open for recruitment
View Trial
BOREAS KRT-232-101
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (BOREAS)
Locations
South Brisbane, Wesley
Diagnosis
Myeloproliferative disorders
Open for recruitment
View Trial
MASTERPLAN
MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease (MASTERPLAN)
Locations
Gold Coast University Hospital
Diagnosis
Pancreatic cancer
Open for recruitment
View Trial
FUZOPRO SHR3162-III-305
Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Locations
Adelaide (Kurralta Park)
Diagnosis
Prostate cancer
Open for recruitment
View Trial
MRDR
Myeloma and Related Disease Registry
Locations
Wesley, South Brisbane, Chermside, Southport
Diagnosis
Multiple myeloma
Open for recruitment
View Trial
OPTIMA 11/0479
Optimal personalised treatment of early breast cancer using multiparameter analysis
Locations
Hobart, Southport
Diagnosis
Breast cancer
Opening soon
View Trial
ZN-D5-001
Phase 1 First in Human Study of ZN-d5 as a Single Agent in Non-Hodgkin Lymphoma and Acute Myeloid Leukemia
Locations
Adelaide (Kurralta Park)
Diagnosis
Diffuse large B-cell lymphoma, Leukaemia
Open for recruitment
View Trial
CK301-101
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Locations
South Brisbane, Adelaide (Windsor Gardens)
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
ESCALADE D8227C00001
Phase 3 randomized, double-blind, placebo-controlled, study assessing the efficacy and safety of acalabrutinib plus rituximab,cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP in subjects ≤65 years of age with previously untreated non-germinal center diffuse large B-cell lymphoma.
Locations
South Brisbane, Wesley, Chermside, Southport
Diagnosis
Lymphoma – B-cell Non Hodgkin’s
Open for recruitment
View Trial
KRYSTAL-10
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation
Locations
Farrer Park
Diagnosis
Colorectal cancer
Open for recruitment
View Trial
HARMONY R3767-ONC-2011
Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
Locations
Hobart
Diagnosis
Skin cancer – melanoma
Open for recruitment
View Trial
ARTISTRY-7 ALKS 4230-007
Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Locations
Wesley
Diagnosis
Ovarian cancer
Open for recruitment
View Trial
KEYNOTE-867 MK-3475-867
Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Participants With Unresected Stages I or II Non Small Cell Lung Cancer (NSCLC)
Locations
Hobart
Diagnosis
Lung cancer
Open for recruitment
View Trial
UNICAB ANZUP1802
Phase II of Single Agent Cabozantinib in Patients With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma Post Immunotherapy or Who Are Unsuitable for Immunotherapy
Locations
Adelaide (Kurralta Park)
Diagnosis
Kidney cancer
Open for recruitment
View Trial
TUGETHER BCT2102
Phase II, Two-arm, Non-comparative, Multicentre Study of Tucatinib (ONT-380), Pembrolizumab and Trastuzumab in Patients With Pre-treated Advanced HER2-positive Breast Cancer
Locations
Hobart
Diagnosis
Breast cancer
Opening soon
View Trial
RADIANT / BAY 88-8223 / 20510
Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
Locations
Chermside, Wesley, South Brisbane, Adelaide (Kurralta Park)
Diagnosis
Prostate cancer
Open for recruitment
View Trial
ASCENT-04 GS-US-592-6173
Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1
Locations
Hobart
Diagnosis
Breast cancer
Open for recruitment
View Trial
ASCENT-03 GS-US-592-6238
Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1
Locations
Hobart
Diagnosis
Breast cancer
Open for recruitment
View Trial
TREMOR
Safety and effectiveness of frameless linac-based stereotactic radiosurgery on tremor in patients with essential tremor or Parkinson’s disease (TREMOR study)
Locations
Epworth Richmond
Diagnosis
Neurological conditions
Open for recruitment
View Trial
Study to Assess SLN124 in Patients With Polycythemia Vera (SLN)
SLN124-004
Locations
Adelaide (Windsor Gardens), Adelaide (Kurralta Park)
Diagnosis
Myeloproliferative disorders
Open for recruitment
View Trial
HBI-8000-303
Study Comparing Investigational Drug HBI-8000 Combined With Nivolumab vs. Nivolumab in Patients With Advanced Melanoma
Locations
Wesley, Chermside, Southport
Diagnosis
Skin cancer – melanoma
Open for recruitment
View Trial
C-POST R2810-ONC-1788
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
Locations
Southport, Adelaide (Kurralta Park)
Diagnosis
Skin cancer – non-melanoma
Open for recruitment
View Trial
BGB-900-105 AdvanTIG-105
Study of BGB-A1217 in Combination With Tislelizumab in Advanced Solid Tumors
Locations
South Brisbane, Adelaide (Windsor Gardens)
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
CAPItello-280
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
Locations
Adelaide (Kurralta Park)
Diagnosis
Prostate cancer
Open for recruitment
View Trial
COSTAR_213410
Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants (COSTAR Lung)
Locations
North Lakes, Chermside, Wesley, Southport, South Brisbane
Diagnosis
Lung cancer
Open for recruitment
View Trial
KEYVIBE-006 MK-7684A-006
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer
Locations
Hobart
Diagnosis
Lung cancer
Open for recruitment
View Trial
EVOKE-02 GS-US-576-6220
Study of Sacituzumab Govitecan-hziy Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations
Locations
Adelaide (Kurralta Park)
Diagnosis
Lung cancer
Open for recruitment
View Trial
STELLAR-001
Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
Locations
Adelaide (Kurralta Park)
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
ASCEND CTC0304
The ASCEND Study: Gemcitabine and Nab-Paclitaxel With CEND-1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Locations
Wesley
Diagnosis
Pancreatic cancer
Open for recruitment
View Trial
MAGMA
The Multi-Arm GlioblastoMa Australasia (MAGMA) Trial is a platform trial that will assess a number of options in standard of care for the management of glioblastoma. Initial questions of interest are: QUESTION 1 whether or not to give a cycle of temozolomide prior to chemoradiotherapy and QUESTION 2: whether to give 6 or 12 cycles of temozolomide after chemoradiotherapy.
Locations
Gold Coast University Hospital, North Lakes, Greenslopes, Concord
Diagnosis
Brain cancer
Open for recruitment
View Trial
ABCPro
Trial is evaluating a new online service for managing self-reported symptoms by people with advanced breast cancer.
Locations
Bowen Icon Cancer Centre
Diagnosis
Breast cancer
Open for recruitment
View Trial
There are no clinical trials currently available
